Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly
Yıl: 2019 Cilt: 3 Sayı: 1 Sayfa Aralığı: 14 - 21 Metin Dili: İngilizce DOI: 10.14744/ejmo.2018.0068 İndeks Tarihi: 21-04-2020
Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly
Öz: Objectives: Acromegaly is a chronic endocrine disorder that is characterized by hypersecretion of growth hormone.The purpose of this study was to evaluate coronary flow reserve (CFR) in patients with acromegaly and investigatewhether there is an association between fibroblast growth factor-23 (FGF-23) and Klotho levels with coronary microcirculation or not.Methods: A total of 54 patients with acromegaly were divided into subgroups: Those with active disease and thosewho are in biochemical remission (serum insulin-like growth factor-1 level was within the normal range). Along with31 healthy volunteers, the patients underwent dipyridamole-stress transthoracic Doppler echocardiography. CFR wascalculated with the ratio of hyperemic to baseline diastolic peak velocities. Klotho and FGF-23 were measured using anenzyme-linked immunosorbent assay.Results: A total of 42 (%77.8) of acromegaly patients had active disease. Acromegaly patients had lower Klotho andFGF-23 levels compared to in controls. Patients with active disease had higher FGF-23 levels and lower Klotho levelswhen compared to patients in remission. CFR levels of active group were lower than remission and controls (p=0.001;p=0.043, respectively). Klotho was strongly associated with CFR levels in patients with active disease (r=0.8, p=0.001).Conclusion: Acromegaly patients have lower levels of Klotho and FGF-23 and CFR.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395–402.
- 2. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327–35.
- 3. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95–102.
- 4. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102–52.
- 5. Minniti G, Jaffrain-Rea ML, Moroni C, Baldelli R, Ferretti E, Cassone R, et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf) 1998;49:101–6.
- 6. Fazio S, Cittadini A, Sabatini D, Merola B, Colao AM, Biondi B, et al. Evidence for biventricular involvement in acromegaly: A doppler echocardiographic study. Eur Heart J 1993;14:26–33.
- 7. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004;89:71–5.
- 8. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 2006;16:101–7.
- 9. Warszawski L, Kasuki L, Sá R, Dos Santos Silva CM, Volschan I, Gottlieb I, et al. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: A prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 2016;19:582–9.
- 10. Kırış A, Erem C, Turan OE, Civan N, Kırış G, Nuhoğlu I, et al. Left ventricular synchronicity is impaired in patients with active acromegaly. Endocrine 2013;44:200–6.
- 11. Vitale G, Pivonello R, Auriemma RS, Guerra E, Milone F, Savastano S, et al. Hypertension in acromegaly and in the normal population: Prevalence and determinants. Clin Endocrinol (Oxf) 2005;63:470–6.
- 12. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and cushing syndrome. Acta Med Austriaca 2000;27:27–31.
- 13. Maldonado Castro GF, Escobar-Morreale HF, Ortega H, Gómez-Coronado D, Balsa Barro JA, Varela C, et al. Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly. Clin Endocrinol (Oxf) 2000;53:313–9.
- 14. Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, et al. Complications of acromegaly: Cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017;20:46–62.
- 15. Vassalli G, Hess OM. Measurement of coronary flow reserve and its role in patient care. Basic Res Cardiol 1998;93:339–53.
- 16. Dimitrow PP. Transthoracic doppler echocardiography–noninvasive diagnostic window for coronary flow reserve assessment. Cardiovasc Ultrasound 2003;1:4.
- 17. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow reserve: Measurement with transthoracic doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol 2001;21:114–22.
- 18. Kawada N, Sakuma H, Yamakado T, Takeda K, Isaka N, Nakano T, et al. Hypertrophic cardiomyopathy: MR measurement of coronary blood flow and vasodilator flow reserve in patients and healthy subjects. Radiology 1999;211:129–35.
- 19. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009;205:385–90.
- 20. Navarro-González JF, Donate-Correa J, Muros de Fuentes M, Pérez-Hernández H, Martínez-Sanz R, Mora-Fernández C, et al. Reduced klotho is associated with the presence and severity of coronary artery disease. Heart 2014;100:34–40.
- 21. Sze L, Bernays RL, Zwimpfer C, Wiesli P, Brändle M, Schmid C, et al. Excessively high soluble klotho in patients with acromegaly. J Intern Med 2012;272:93–7.
- 22. Akgul E, Tokgozoglu SL, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I, et al. Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 2010;27:990–6.
- 23. Yaron M, Izkhakov E, Sack J, Azzam I, Osher E, Tordjman K, et al. Arterial properties in acromegaly: Relation to disease activity and associated cardiovascular risk factors. Pituitary 2016;19:322–31.
- 24. Izzard AS, Emerson M, Prehar S, Neyses L, Trainer P, List EO, et al. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res 2009;19:413–9.
- 25. Courville C, Mason VR. The heart in acromegaly. Arch Intern Med 1938;61:704–13.
- 26. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE, et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993;88:993–1003.
- 27. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol 2012;52:857–64.
- 28. Garcia JA, Incerpi EK. Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide. Arq Bras Cardiol 2008;90:409–16.
- 29. Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A, et al. Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J Clin Endocrinol Metab 2003;88:4105–9.
- 30. Dąbrowska AM, Tarach JS. Soluble klotho protein as a novel serum biomarker in patients with acromegaly. Arch Med Sci 2016;12:222–6.
- 31. Jawiarczyk-Przybyłowska A, Halupczok-Żyła J, Bolanowski M. Soluble α-klotho-a new marker of acromegaly? Endokrynol Pol 2016;67:390–6.
- 32. Kim SJ, Cheresh P, Eren M, Jablonski RP, Yeldandi A, Ridge KM, et al. Klotho, an antiaging molecule, attenuates oxidant-induced alveolar epithelial cell mtDNA damage and apoptosis. Am J Physiol Lung Cell Mol Physiol 2017;313:L16–26.
- 33. Kan K, Kizilgul M, Culha C, Arslan MS, Apaydin M, Caliskan M, et al. Fibroblast growth factor-23 concentrations in polycystic ovary syndrome. Turk J Biochem 2017. Doi: 10.1515/tjb-2016- 0307.
- 34. Kizilgul M, Kan S, Beysel S, Apaydin M, Ozcelik O, Caliskan M, et al. Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes? Arch Endocrinol Metab 2017;61:562–6.
- 35. Reyes-Garcia R, Garcia-Martín A, García-Fontana B, MoralesSantana S, Rozas-Moreno P, Muñoz-Torres M, et al. FGF23 in Type 2 diabetic patients: Relationship with bone metabolism and vascular disease. Diabetes Care 2014;37:e89–90.
- 36. Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S, et al. Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr J 2007;54:481–4.
| APA | TAKIR M, AKSU F (2019). Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. , 14 - 21. 10.14744/ejmo.2018.0068 |
| Chicago | TAKIR Mümtaz,AKSU Feyza Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. (2019): 14 - 21. 10.14744/ejmo.2018.0068 |
| MLA | TAKIR Mümtaz,AKSU Feyza Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. , 2019, ss.14 - 21. 10.14744/ejmo.2018.0068 |
| AMA | TAKIR M,AKSU F Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. . 2019; 14 - 21. 10.14744/ejmo.2018.0068 |
| Vancouver | TAKIR M,AKSU F Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. . 2019; 14 - 21. 10.14744/ejmo.2018.0068 |
| IEEE | TAKIR M,AKSU F "Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly." , ss.14 - 21, 2019. 10.14744/ejmo.2018.0068 |
| ISNAD | TAKIR, Mümtaz - AKSU, Feyza. "Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly". (2019), 14-21. https://doi.org/10.14744/ejmo.2018.0068 |
| APA | TAKIR M, AKSU F (2019). Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology, 3(1), 14 - 21. 10.14744/ejmo.2018.0068 |
| Chicago | TAKIR Mümtaz,AKSU Feyza Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology 3, no.1 (2019): 14 - 21. 10.14744/ejmo.2018.0068 |
| MLA | TAKIR Mümtaz,AKSU Feyza Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology, vol.3, no.1, 2019, ss.14 - 21. 10.14744/ejmo.2018.0068 |
| AMA | TAKIR M,AKSU F Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 14 - 21. 10.14744/ejmo.2018.0068 |
| Vancouver | TAKIR M,AKSU F Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly. Eurasian Journal of Medicine and Oncology. 2019; 3(1): 14 - 21. 10.14744/ejmo.2018.0068 |
| IEEE | TAKIR M,AKSU F "Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly." Eurasian Journal of Medicine and Oncology, 3, ss.14 - 21, 2019. 10.14744/ejmo.2018.0068 |
| ISNAD | TAKIR, Mümtaz - AKSU, Feyza. "Association between Coronary Flow Reserve, Klotho and Fibroblast Growth Factor 23 in Patients with Acromegaly". Eurasian Journal of Medicine and Oncology 3/1 (2019), 14-21. https://doi.org/10.14744/ejmo.2018.0068 |
